These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23528371)

  • 1. PTCL therapies: a review of treatment and outline of novel therapies.
    Khan N; Cheson BD
    Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing existing approaches to peripheral T-cell lymphoma.
    Foss FM
    Semin Hematol; 2010 Apr; 47 Suppl 1():S8-10. PubMed ID: 20359584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
    d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
    Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel targeted therapies in peripheral T cell lymphoma.
    Jagadeesh D; Smith MR
    Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies for peripheral T-cell lymphomas.
    Foss FM
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T-cell lymphoma: new therapeutic strategies.
    Petrich AM; Rosen ST
    Oncology (Williston Park); 2013 Sep; 27(9):878-84. PubMed ID: 24282984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of advanced-stage peripheral T-cell lymphomas.
    Kimby E
    Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
    Chen AI; Advani RH
    J Natl Compr Canc Netw; 2008 Apr; 6(4):428-35. PubMed ID: 18433608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutic advancements in peripheral T-cell lymphoma.
    Reddy NM; Evens AM
    Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment and future prospects for peripheral T-cell lymphoma.
    Eyre TA; Collins GP
    Drugs Today (Barc); 2013 Oct; 49(10):631-46. PubMed ID: 24191256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.